IL6 and cancer: Cancer patients, in general, have elevated levels of cytokines, interleukin-6 and tumor necrosis factor-alpha which tend to increase following immunotherapy [19]. They alter the pharmacokinetics of drugs by downregulating the expression and enzyme activity of the CYP3A4, the enzyme responsible for the metabolism of DOACs.